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Abstract
Purpose Kidney cancer is one of the fastest rising cancers
worldwide. We aimed to examine the trends in incidence,
mortality, and survival for this cancer in Canada.
Methods Incidence data for kidney cancer for 1986–2010
were from the Canadian Cancer Registry and the National
Cancer Incidence Reporting System. These data were only
available up to 2007 for the province of Quebec and con-
sequently for the same year nationally, for Canada. Mor-
tality data for 1986–2009 were from the Canadian Vital
Statistics Death Database. Changes in age-standardized
rates were analyzed by Joinpoint regression. Incidence
rates were projected to 2025 using a Nordpred age-period-
cohort model. Five-year relative survival ratios (RSR) were
analyzed for 2004–2008 and earlier periods.
Results Between 1986 and 2007, the age-standardized
incidence rate (ASIR) per 100,000 rose from 13.4 to 17.9 in
males and 7.7 to 10.3 in females. Annual increases in ASIR
were greatest for age groups\65 years (males) and C65 years
(females). The ASIRs increased significantly over time in both
sexes for renal cell carcinoma (RCC) but not for other kidney
cancer types. RCC rates are projected to increase until at least
2025. Mortality rates decreased only slightly in each sex since
1986 (0.4 %/year in males; 0.8 %/year in females). The
5-year RSR for kidney cancer was 68 % but differed largely
by morphology and age, and has increased slightly over time.
Conclusions The incidence rate of kidney cancer in Canada
has risen since at least 1986, led largely by RCC. Increasing
detection of incidental tumors, and growing obesity and
hypertension rates are possible factors associated with this
increase. Greater prevention of modifiable risk factors for
kidney cancer is needed.
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Abbreviations
AAPC Average annual percent change
APC Annual percent change
ASIR Age-standardized incidence rate
RSR Relative survival ratio
Background
Kidney cancer will be responsible for an estimated 6,000
new cases and 1,750 deaths in Canada in 2014, making it
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the eighth most common cancer and the twelfth leading
cause of cancer death [1]. In developed countries, kidney
cancer represents approximately 2–4 % of all new cancers,
with incidence rates ranging from 7 to 22 per 100,000
among males and 4 to 13 per 100,000 among females [2,
3]. Incidence rates are higher in developed countries than
in the developing world [4].
Historically, cancers of the renal pelvis were grouped
with those of the renal parenchyma when referring to
kidney cancer. However, it is now recognized that the
former are essentially urothelial (bladder) cancers [5].
Using this definition, approximately 90 % of all kidney
cancers in Canadian adults occur in individuals 45 years of
age and older [6]. The most frequent morphological type is
renal cell carcinoma (RCC), which represents about 80 %
of all kidney cancers in Canada [6]. The remainder repre-
sents unspecified malignant neoplasms (11.0 %) and car-
cinomas (1.8 %), transitional and squamous cell
carcinomas (2.0 %), and other specified malignant neo-
plasms (0.7 %) and carcinomas (0.7 %). RCC consists
mostly of two histological types: clear cell carcinoma
([80 %) and papillary (10 %) [7].
Established risk factors for kidney cancer are smoking,
obesity, hypertension, inherited genetic conditions (e.g.,
Von Hippel-Lindau syndrome), end-stage kidney disease,
having a first-degree relative with kidney cancer, and a
birth defect known as horseshoe kidney [8]. Possible risk
factors include exposure to radiation, arsenic in drinking
water, and some occupational exposures. Among occu-
pational exposures, trichloroethylene (TCE), a chemical
used in dry cleaning, has been most commonly impli-
cated in kidney cancer risk [9, 10] and appears to be
more strongly associated with clear cell RCC [11]. Cer-
tain medications may have a role in increasing the risk of
kidney cancer, including acetaminophen and non-aspirin
NSAIDs, but there is little consistency for this associa-
tion [12]. On the contrary, moderate alcohol consumption
appears to be associated with a reduction in risk of RCC
[13, 14].
Given that known genetic conditions explain up to 5 %
of RCC cases [15], increases in incidence rates may be
explained by improvements in detection as well as lifestyle
and behavioral causes. Of the lifestyle factors, tobacco use,
excess body weight, and uncontrolled blood pressure are
the most important modifiable risk factors at a population
level.
Several countries have reported rising incidence rates of
kidney cancer [2, 3, 7], particularly for RCC, but a detailed
analysis of such trends in Canada has not yet been per-
formed. Therefore, the objectives of this study were to
analyze the long-term trends in incidence and mortality,
examine survival, and calculate projected incidence rates
up to 2025 for kidney cancer in Canada.
Methods
Data sources
Incidence data for 1986–1991 were obtained from the
National Cancer Incidence and Reporting System and for
1992–2010 from its successor, the Canadian Cancer Reg-
istry [16].
Each provincial and territorial cancer registry supplies
data on cancer patients and tumors in a standard format.
Subsequent changes to registry data due to errors or
omissions found in the data are also transmitted to Statis-
tics Canada. Each provincial and territorial cancer registry
has the ability to add, update, and delete records. A series
of core edits and an internal record linkage process to
identify duplicate records are used to build and maintain
the Canadian Cancer Registry [16].
Kidney cancer cases were defined based on the Inter-
national Classification of Diseases for Oncology, Third
Edition (ICD-O-3) [17] as topography C64.9 (kidney, not
otherwise stated) excluding morphologies 9050–9055,
9140, and 9590–9989. Cancers of the renal pelvis (C65.9)
were excluded because these are now recognized as being
urothelial cancers [5]. By way of comparison, for
2003–2007, the incidence is reduced from 21,335 to 20,052
when renal pelvis is excluded from our data. For data prior
to 1992 from the National Cancer Incidence and Reporting
System, equivalent ICD-9 site codes [18] and ICD-O-1
histology codes [19] were used.
Cancers of the renal parenchyma were examined
according to morphology, as RCC or ‘‘other.’’ Children
under 15 years of age were excluded from our analysis
because the predominant type of renal cancer that develops
in this group is nephroblastoma.
Mortality data were from the Canadian Vital Statistics
Death Database [20] and were selected based on classifi-
cation C64 used in the International Classification of Dis-
ease, version 10 [21]. Population estimates, which were
used to derive rates, are from Statistics Canada’s Demo-
graphic Estimates Compendium 2012 [22].
Statistical analysis
Incidence and mortality rates
Incidence data for one Canadian province (i.e., Quebec)
were only available up to 2007 despite data for all other
provinces being available to 2010. As a result, we restricted
our analysis of national incidence rates for Canada up to
2007 but examined rates for provinces up to their latest
available year of data. Cancer mortality data, on the other
hand, were available up to 2009 for all regions. Canadian
territories (Yukon, Northwest Territories, Nunavut) were
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excluded from region-specific analyses presented in this
paper because of the small number of annual new cases and
deaths in these jurisdictions. Data from the territories were,
however, included in the analyses of national rates for
Canada.
Age-standardized incidence rates (ASIR) for 1986–2007
for Canada (and up to 2010 for all provinces except Quebec)
and age-standardized mortality rates (ASMR) for
1986–2009 for Canada and all provinces were derived using
the direct method and standardized to the 1991 Canadian
population [1]. Trends over time were analyzed by calcu-
lating the annual percent change (APC) and average annual
percent change (AAPC) in age-standardized rates using
Joinpoint regression [23]. The minimum number of obser-
vations from a joinpoint to either end of the data and between
joinpoints was set to five.
Incidence rate projections
The Nordpred Power5 age-period-cohort model was used
to project Canada incidence rates for five-year periods from
2008–2012 to 2023–2027. Nordpred is based on an age-
period-cohort Poisson regression model but has enhance-
ments that overcome difficulties in the standard Poisson
model and improve projection accuracy [24, 25]. Future
values are estimated by projecting forward the model’s
linear time trend, with successive reductions in each per-
iod, while fixing the period and cohort effects. Nordpred
default settings were used for all projections. A detailed
description of the projection model and methods can be
found elsewhere [26].
Survival
Relative survival analyses were based on a publicly available
algorithm [27] to which minor adaptations were made.
Expected survival proportions were derived from both pub-
lished [28] and unpublished annual sex-specific complete
provincial life tables. The focus of this analysis was on all
primary cancer cases aged 15–99 at diagnosis. Mortality
follow-up through December 31, 2008, was determined by
record linkage of the Canadian Cancer Registry to the
Canadian Vital Statistics Deaths database and from infor-
mation reported by provincial and territorial cancer regis-
tries. Data from the province of Quebec were excluded for
survival analyses only because the method of ascertaining
the date of diagnosis of cancer cases in this province differed
from that of other provincial cancer registries and because of
issues in correctly ascertaining the vital status of cases
diagnosed in Quebec within the Canadian Cancer Registry.
Data for the Canadian territories (Yukon, Northwest Terri-
tories, Nunavut) and the province of Prince Edward Island
are not presented separately because of the small number of
cases, which do not allow for precise estimates to be calcu-
lated. Five-year relative survival ratio (RSR) estimates were
derived using the period method for 2004–2008 and the
cohort method for earlier time periods of 1992–1996 and
1998–2002. Further detail on the survival methodology is
provided elsewhere [29].
Results
Between 1986 and 2007, the ASIR of kidney cancer in
Canada rose from 13.4 to 17.9 per 100,000 in males and 7.7 to
10.3 per 100,000 in females (Table 1), representing an
AAPC of 1.2 % per year in males and 0.9 % per year in
females over this period. The greatest increase in incidence
rate in males occurred between 1986 and 1990, when the
APC was 3.5 %. A second period of significant increase in
males occurred from 1998 to 2007, when the APC was
1.7 %. In females, the rate rose significantly by 2.0 % per
year from 1998 to 2007.
Age-standardized mortality rates were less than half of
the corresponding incidence rates and declined only
slightly since 1986 (Table 1). The ASMR declined by
0.4 % per year in males and 0.8 % per year in females.
Trends by age and sex
The age-specific incidence rate of RCC generally rose
quickly after age 50 for both sexes and followed the trend
for all kidney cancer types combined. However, this rate
dropped sharply after the 75–79 age group (Fig. 1). The
‘‘unknown’’ histology group was responsible for the
continuing increasing trend in the older age groups beyond
75 years.
Among males, the ASIR of kidney cancer has increased
over time across all age groups (Fig. 2), with the biggest
increases in those under age 65. In contrast, incidence rates
have increased most among females over the age of 65.
When RCC was examined separately by age group, similar
trends were observed, with higher AAPC in most age
groups (Fig. 3). In particular, the AAPC was more than
double in the two oldest age groups in males (65–74 years
and 75 ? years).
Mortality from kidney cancer (data not shown) has
generally declined across all age groups, with the strongest
declines among those aged 15–44 years (males: –2.5 % per
year; females –3.1 % per year). The only exceptions were
an increase in the mortality rate among males aged
C75 years (0.7 % per year) and stable mortality rates
among females aged C65 years.
Unlike for other kidney cancer subtypes, the ASIR has
increased significantly since 1986 for RCC in both males
(1.9 % per year) and females (1.4 % per year) of all ages
Cancer Causes Control (2014) 25:1271–1281 1273
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(Fig. 4). Among males, the ASIR for RCC has risen by
4.1 % per year between 2003 and 2007. Projections for the
ASIR of RCC in males and females show an upward tra-
jectory until at least 2025, reaching rates of 17.9 per
100,000 in males and 8.7 per 100,000 for females. Little or
no change for other kidney cancer subtypes is expected.
Trends by province
Based on data for 1986–2010 (up to 2007 for Quebec), the
ASIR was nearly two times higher among males than
females in most provinces (Table 2). Provincial ASIRs
were generally higher in eastern Canada (i.e., New
Brunswick, Newfoundland & Labrador, Nova Scotia, and
Prince Edward Island).
When comparing the change in the ASIR over time, the
largest APCs for males over the period of 1986–2010 were
observed in Ontario (since 2003), New Brunswick, and
Newfoundland & Labrador. In females, the largest APCs
were in Quebec (since 1997). With the exception of males in
Manitoba, APCs were lowest in western Canada (i.e., British
Columbia, Alberta, and Saskatchewan) in both sexes.
Five-year relative survival
Individuals diagnosed with kidney cancer in Canada in
2004–2008 were estimated to have 68 % chance of living
at least five more years after diagnosis as compared to
similar people in the general population (Table 3). The
five-year RSR for those with RCC of the kidney was
estimated at 72 %—considerably higher than for cases
diagnosed with another or unknown histology.
Estimated five-year RSRs were slightly higher among
females than males and progressively declined with advancing
age from 85 % among those aged 15–44 years at diagnosis to
54 % among those aged 75–99. Age-standardized five-year
RSR ranged from a high of 73 % among those diagnosed in the
province of Ontario to a low of 58 % in Manitoba. In all other
provinces, RSRs were generally in the mid-60 s.
Absolute increases in survival from 1992–1996 to
2004–2008 by sex, age group, and histology were consistent
with the increase observed overall for kidney cancer (7
percentage points). The largest provincial increases in RSR
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analysis [30], have nearly doubled since 1970. The greater
rate of increase in males under age 65 and in females over
65 years possibly reflects the prevalence of obesity in
Canada, whereby self-reported obesity is markedly more
prevalent among males up to the age group of 55–64 but is
more prevalent in females after the age of 75 years [31].
The plateauing of incidence rates for RCC followed by a
drop in rates after age 75 in Canadian males and females
(Fig. 1) may be due to less rigorous diagnostic testing and
microscopic confirmation of cases compared to all other
types of kidney cancers in this age group [32].
If historical trends continue, rates of RCC in Canada are
projected to rise by about 15 % among males by 2025
(Fig. 4), but increase only marginally among females.
Similar patterns of increase are expected in most parts of
the world [33]. Aside from RCC, the incidence rate for
other histological types has been relatively stable in Can-
ada in recent years, and little change is expected over the
next decade. Our projected future rates of kidney cancer
are estimates based on the assumption that historical trends
will continue. Actual future values may differ as a result of,
for example, changes in prevention programs and the
prevalence of key risk factors.
The rising incidence of kidney cancer is consistent with
trends observed by others over a similar time period [32,
34–36]. The increasing use of imaging technologies (e.g.,
ultrasonography, computed tomography, magnetic reso-
nance imaging) has likely resulted in greater incidental
detection of kidney cancer [37, 38], especially of smaller
tumors [32, 39]. However, such technological advance-
ments cannot entirely account for the upward trends [35] as
incidence rates have continued to increase despite the fact
that improvements in detection occurred primarily during
the late 1980s to early 1990s. Despite increased RCC rates
associated with period-related factors, birth cohorts since
the 1960s in the USA also show rapidly increasing inci-
dence rates compared to earlier cohorts [40]. This suggests
that risk factors and exposures unique to recent generations
account to some degree for the rising incidence of RCC.
However, the relative contribution of changes in risk factor
prevalence in comparison with changes in diagnostic
practices remains unclear.
Risk factors
Several modifiable risk factors may be contributing to the
upward incidence trend in Canada, including obesity,
hypertension, and smoking. However, the relative contri-
bution of each of the above risk factors to the temporal
trend in kidney cancer is difficult to ascertain given the
possible confounding effect of increasing detection of this
disease [41].
The prevalence of obesity has been increasing in Canada
over the past 25 years [42], a trend that has mirrored the
rise in kidney cancer rates. A positive association between
body mass index (BMI) and kidney cancer has been pre-
viously reported in Canada, with the greatest risk in the
most obese [43, 44]. Obesity is attributed to 30–40 % of
kidney cancer cases [7] and it is strongly linked to clear
cell RCC in a dose–response fashion [45, 46].
Hypertension is a well-established risk factor for kidney
cancer, independent of obesity, and elevates the risk of
RCC in a dose-dependent manner [7]. In Canada, there has
been a rising trend in the prevalence of measured hyper-
tension since at least the mid-1980s [47, 48]. Even well-































Fig. 1 Age-specific incidence
rates of renal cell carcinoma
(RCC) and all kidney cancer
subtypes (including RCC but
excluding renal pelvis), Canada,
2003–2007
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of kidney cancer, with the relative risk of cancer being only
slightly lower than among people with poorly controlled
blood pressure [49].
Smoking is a well-established risk factor for RCC [50],
and despite its declining prevalence in Canada, likely
continues to contribute to new RCC cases. Smoking has
been implicated as a causal factor in up to 20 % of kidney
cancer cases [15], and the association with smoking
appears to be stronger for cancers of the renal pelvis than
the renal parenchyma [51]. Among active smokers, the risk
of kidney cancer increases with the number of cigarettes
smoked per day [52], with at least a 50 % increased risk of
kidney cancer [53]. Moreover, there is evidence that
exposure to second-hand smoke also increases risk, with
longer duration and multiple sources of exposure leading to
higher risk [54, 55].
Provincial variations in kidney cancer incidence rates
likely reflect regional differences in the prevalence of risk
factors. First, the higher incidence rates of kidney cancer in
Prince Edward Island, Nova Scotia, New Brunswick, Que-
bec, Saskatchewan, and Manitoba could partly be explained
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incidence rates (ASIR) of
kidney cancer (excluding renal
pelvis) by age group and sex,
Canada, 1986–2007. AAPC
average annual percent change;
APC annual percent change.
Change point observed only in
ASIR for females aged 75?
years (in 1992). * statistically
significantly different from zero
(two-sided p \ 0.05)
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compared to other parts of Canada [56]. Second, adult
obesity rates have tended to be higher in eastern Canada (i.e.,
provinces of Nova Scotia, New Brunswick, Prince Edward
Island, and Newfoundland & Labrador) and two Territories
(Northwest Territories and Nunavut) but have generally
increased across the country between 2000 and 2011 [57].
Third, in 2006–07, the prevalence of hypertension was
highest in eastern Canada, followed by the provinces of
Saskatchewan, Manitoba, and Ontario. Finally, exposure to
inorganic arsenic in drinking water and food (a possible
cause of kidney cancer [58]) also varies across the country,
with greatest amounts of geologic deposits in the Yukon,
northern British Columbia, Nunavut Islands, eastern Can-
ada, and a few areas in southern Ontario [59].
Mortality
The mortality rates for both sexes in 2007 have decreased
only slightly compared to 1986. The small decline is
consistent with other studies in Canada [34] and in Europe
[2], where the advent of improved diagnostics in the early
1990s, a greater understanding of the molecular biology of
the disease, surgical advances, and systemic chemothera-
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15-44 years (AAPC = 1.7%*)
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55-64 years (AAPC = 1.8%* (1986-2007); APC = 1.1%* [1990-2007])
65-74 years (AAPC = 1.1%*)
75+ years (AAPC = 1.7%*)
Fig. 3 Age-standardized
incidence rates (ASIR) of RCC
by age group and sex, Canada,
1986–2007. RCC renal cell
carcinoma; AAPC average
annual percent change; APC
annual percent change.
* statistically significantly
different from zero (two-sided
p \ 0.05)
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Survival
The diverging trends in incidence and mortality rates suggest
an improvement in survival. The age-standardized five-year
RSR in Canada has increased by 7 % points (60 % to 67 %)
from 1992/1996 to 2004/2008. Part of this improvement may
be due to the identification of an increasing proportion of
early-stage tumors with better prognosis [60], which has
been observed by several authors [32, 41].
In the province of Manitoba in 2010, 50.0 % of new
kidney cancer diagnoses were stage I and 24.7 % were
stage IV [61], suggesting a potentially important role for
the early detection of this cancer. Although stage IV
(metastatic disease) is fatal for the vast majority of people,
individuals with stage I are expected to have a good
prognosis [62], with data from the USA showing that the
five-year relative survival at localized stage to be 91.7 %
[63].
Table 2 Annual percent change in age-standardized incidence rates for kidney cancer (excluding renal pelvis), ages 15 ? , by sex in Canada
and provinces*
Males Females
ASIR (per 100,000) APC (95 % CI) Changepoint ASIR (per 100,000) APC (95 % CI) Changepoint
Canada 17.9 1.7 (1.1,2.3) 1998 10.3 2.0 (1.0,3.0) 1998
Province
British Columbia 11.0 -0.4 (-0.8,0.0) 5.2 -0.4 (-0.9,0.1)
Alberta 15.6 0.4 (-0.2,0.9) 8.6 0.2 (-0.4,0.7)
Saskatchewan 17.9 0.6 (-0.2,1.4) 9.8 1.0 (0.1,1.8)
Manitoba 23.0 1.8 (1.0,2.6) 10.0 -0.5 (-2.6,1.7) 2000
Ontario 17.6 2.9 (0.6,5.2) 2003 9.0 1.4 (1.0,1.8)
Quebec 18.4 1.0 (0.7,1.3) 10.2 2.0 (1.2,2.8) 1997
New Brunswick 28.9 2.6 (1.6,3.5) 10.4 1.2 (0.1,2.3)
Nova Scotia 22.1 1.6 (0.9,2.2) 13.5 1.7 (1.0,2.4)
Prince Edward Island 22.1 1.2 (-0.5,2.9) 10.6 1.9 (-0.1,3.9)
Newfoundland & Labrador 23.7 2.7 (1.7,3.6) 13.2 1.7 (-0.1,3.5)
APC annual percent change, ASIR age-standardized incidence rate, CI confidence interval
* Canada and Quebec ASIR is for 2007 and APC for 1986-2007; ASIR for all other provinces is for 2010 and APC for 1986–2010
 Change point refers to the year in which the APC changed. Therefore, the associated APC refers to annual percent change from that point to the
year 2010 (or 2007 for Canada and Quebec). If no change point is indicated, then the APC refers to the average annual percent change (AAPC)
over the period of 1986–2010 (or 1986–2007 for Canada and Quebec)

















RCC, males (AAPC = 1.9%*; APC = 4.1%* [2003-2007])
RCC, females (AAPC = 1.4%*; APC = 1.4%*[1986-2007])
Other, males (AAPC = -1.1%; APC = -0.5% [1993-2007])
Other, females (AAPC = -1.1%; APC = 0.5% [1994-2007])
Fig. 4 Age-standardized
incidence rates (ASIR) for RCC
and other kidney subtypes
(excluding renal pelvis) by sex
in Canada for 1986–2007 and
projections for 2008–2025. RCC
renal cell carcinoma; AAPC
average annual percent change;
APC annual percent change.
‘Other’ includes all cases that
are not RCC. * statistically
significantly different from zero
(two-sided p \ 0.05)
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The overall five-year RSR of kidney cancer of 68 %
(unadjusted for age) is close to the average survival of 63 %
for all cancers combined in Canada [1]. The RSR depended
strongly on morphology (with higher survival for RCC
versus other types), and age (with higher survival for
younger ages). In comparison with Canada, five-year relative
survival from kidney cancer appears to be somewhat lower
across Europe [64] and slightly higher in the USA [63].
Implications
While the role of increasing detection of incidental tumors
cannot be ruled out, research to date also suggests an
important role for lifestyle risk factors in the etiology of
kidney cancer. Obesity is identified as an important target
for intervention [4, 58,] with some research suggesting that
obesity at any stage of life affects the risk of RCC [65].
Managing excess weight may not only help prevent kidney
cancer but can also have benefits for other cancers
implicated by excess weight, such as cancers of the liver,
thyroid, and esophageal adenocarcinoma [66–68].
Some research [69, 70] suggests that controlling blood
pressure can help lower RCC risk. In addition, quitting
smoking may lower the risk of kidney cancer for smokers
and have collateral benefits for non-smokers exposed to
environmental tobacco smoke. Quitting smoking for more
than 10 years can produce the greatest reduction in kidney
cancer risk, and this benefit increases with longer periods
of cessation [55]. However, given the stronger association
of smoking with cancers of the renal pelvis compared to
RCC, reductions in smoking rates may have only a mar-
ginal impact on overall kidney cancer trends.
Although screening for kidney cancer is advised for
patients and their families who have genetic conditions such
as Von Hippel-Lindau syndrome, there is currently little
evidence to support the effectiveness of routine screening for
RCC in the general population because of the low prevalence
of the disease and the high costs of imaging [71].
Table 3 Estimated five-year relative survival ratios (%) for kidney cancer (excluding renal pelvis) by time period, histology, sex, age group, and
province in Canada*, 1992-2008
Five-year RSR (95 % CI)
unadjusted for age
Age-standardized five-year RSR (95 % CI)
2004–2008 1992–1996 1998–2002 2004–2008
Histology
All kidney cancers 68 (67–69) 60 (59–61) 64 (63–65) 67 (66–68)
Renal cell carcinoma 72 (71–73) 65 (63–66) 68 (67–69) 71 (70–72)
Other & unspecified 43 (41–46) 42 (39–45) 42 (39–44) 48 (45–50)
Sex
Males 67 (66–68) 59 (58–61) 62 (61–64) 66 (65–67)
Females 69 (68–71) 62 (61–64) 66 (65–68) 69 (68–70)
Age group
15–44 85 (83–87) 79 (76–82) 84 (81–86) 85 (83–87)
45–54 77 (75–78) 69 (66–71) 74 (72–76) 77 (75–78)
55–64 71 (70–73) 63 (61–66) 68 (66–70) 71 (70–73)
65–74 66 (64–68) 60 (58–62) 62 (60–64) 66 (64–68)
75–99 54 (51–56) 48 (45–51) 50 (47–53) 54 (51–56)
Province
British Columbia 62 (59–64) 58 (56–61) 57 (55–60) 62 (60–64)
Alberta 65 (62–67) 59 (56–62) 63 (60–65) 63 (61–66)
Saskatchewan 63 (59–68) 52 (47–57) 61 (56–65) 64 (60–68)
Manitoba 58 (54–62) 53 (49–57) 59 (55–63) 58 (55–62)
Ontario 73 (71–74) 63 (62–65) 67 (66–69) 72 (70–73)
New Brunswick 68 (64–73) 55 (50–60) 64 (59–68) 66 (62–70)
Nova Scotia 67 (63–71) 64 (59–69) 62 (58–66) 67 (63–71)
RSR relative survival ratio, CI confidence interval
* Excludes the province of Quebec. Data from the province of Quebec were excluded because the method of ascertaining the date of diagnosis of
cancer cases in this province differed from that of other provincial cancer registries and because of issues in correctly ascertaining the vital status
of cases diagnosed in Quebec within the Canadian Cancer Registry. Data for the province of Newfoundland and Labrador are not shown as they
are artifactually high
 Age group-specific results were not age-standardized
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Conclusion
The kidney cancer incidence rate in Canada has been rising
since at least 1986, led largely by the upward trend in RCC.
The increase in RCC is projected to continue into the
future. Detection of incidental tumors, obesity, and
hypertension, and possibly smoking, have likely contrib-
uted to the observed increase. While the kidney cancer
mortality rates have been decreasing and survival increas-
ing during the most recent decade, five-year relative sur-
vival remains moderate compared to the survival for all
cancers combined in Canada.
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